cjc1295 and ipamorelin results cjc-1295 timeline fat loss FROM 208 Lb ➡️ 172 Lb 24% ➡️ 12.2% cjc1295 ipamorelin clinical studies human

doi: 10.1002/ijc.11387 211 HuangBWarnerMGustafssonJA

In rodent Achilles tendon transection models: BPC-157 administration led to: Higher tensile strength Faster load-bearing capacity Improved structural continuity These are functional endpoints meaning the tissue wasnt just healing histologically, but mechanically

Goal: Selectively clear senescent cells by disrupting the nuclear FOXO4p53 interaction so freed p53 triggers apoptosis demonstrated in preclinical (mouse) work only, not established in humans [1] [2] Schedule: Daily subcutaneous injections across a 16-week course with gradual dose escalation

What are the primary research applications for BPC-157